PharmaPoint: Seasonal Influenza Vaccines France Drug Forecast and Market Analysis

Description:

GlobalData has released its new Country report, “PharmaPoint: Seasonal Influenza Vaccines France Drug Forecast and Market Analysis”. Seasonal Influenza is a respiratory infection caused by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. The market is heavily driven by the sales of prophylactic vaccine treatments to prevent infection. Currently, trivalent intramuscular vaccines such as Sanofi's Fluzone and Vaxigrip, GlaxoSmithKline's Fluarix and FluLaval and Novartis' Fluvirin garner the majority stake of the market. However, with the entrance of vaccines with novel routes of administration, such as AstraZeneca's intranasal FluMist and Sanofi's Fluzone IntraDermal, GlobalData projects a dramatic shift favoring the adoption of such vaccines over the traditional intramuscular vaccines. GlobalData also anticipates that manufacturers that launch quadrivalent formulations will steal market share, patient share, and revenue from the trivalent influenza vaccines currently available.

The French influenza vaccine market is valued at approximately $47.8 million in 2012. The projected drivers of sales growth include the growth of the elderly population and introduction of quadrivalent seasonal influenza vaccines. Sanofi is the market leader in France. The French influenza manufacturer controls over a third of the influenza vaccine market in this country, with a portfolio that includes trivalent intramuscular influenza vaccines Vaxigrip and Mutagrip and an intradermal vaccine, Intanza. Sanofi's home field advantage and novel products have enabled it to dominate the French market.

Scope

- Overview of seasonal influenza, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in France including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in France from 2012 to 2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the France seasonal influenza market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for seasonal influenza
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012 to 2022 in France.

Contents:

1
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Symptoms
3.3 Prognosis
4 Disease Management
4.1 Influenza Vaccination Policy
4.2 France
4.2.1 Influenza Vaccination Recommendations and Policies
4.2.2 Clinical Practice
5 Competitive Assessment
5.1 Overview
5.2 Strategic Competitor Assessment
5.3 Product Profiles - Major Brands
5.3.1 Fluarix/FluLaval
5.3.2 Vaxigrip/Mutagrip
5.3.3 Influvac
5.3.4 Fluad
5.3.5 Fluzone ID (Intradermal)
5.3.6 Optaflu
6 Opportunity and Unmet Need
6.1 Overview
6.2 Unmet Needs
6.2.1 Higher level of patient awareness
6.2.2 Increased efficacy in the elderly and young children (<2 years old)
6.2.3 Improved vaccine side-effect profiles
6.2.4 More efficient vaccine manufacturing process
6.2.5 More cost-effective vaccines
6.3 Gap Analysis
6.4 Opportunities
6.4.1 Expanded breadth of protection against viral strains
6.4.2 Increased duration of protection
6.4.3 T-cell involvement
7 Pipeline Assessment
7.1 Overview
8 Market Outlook
8.1 France
8.1.1 Forecast
8.1.2 Key Events
8.1.3 Drivers and Barriers
9 Appendix
9.1 Bibliography
9.2 Abbreviations
9.3 Methodology
9.4 Forecasting Methodology
9.4.1 Vaccine Coverage
9.4.2 Vaccines Included
9.4.3 Key Launch Dates
9.4.4 Influenza Vaccine Tender System Assumptions
9.4.5 General Pricing Assumptions
9.4.6 Individual Vaccine Assumptions
9.5 Physicians and Specialists Included in this Study
9.6 Primary Research - Prescriber Survey
9.7 About the Authors
9.7.1 Authors
9.7.2 Global Head of Healthcare
9.8 About Us
9.9 Contact Us
9.10 Disclaimer

1.1 List of Tables
Table 1: Notable Influenza Pandemics
Table 2: Symptoms of Influenza
Table 3: Influenza Vaccination Recommendation Committees
Table 4: Leading Influenza Vaccines, 2012
Table 5: Product Profile - Fluarix
Table 6: Fluarix SWOT Analysis, 2012
Table 7: Product Profile - Vaxigrip
Table 8: Laboratory-Confirmed Influenza Infection Rates in Vaccine or Placebo Recipients and their Household Contacts
Table 9: Vaxigrip SWOT Analysis, 2012
Table 10: Product Profile - Influvac
Table 11: Influvac SWOT Analysis, 2012
Table 12: Product Profile - Fludad
Table 13: Fludad SWOT Analysis, 2012
Table 14: Product Profile - Fluzone ID
Table 15: Non-inferiority Comparison of Fluzone ID and IM Vaccines
Table 16: Fluzone ID SWOT Analysis, 2012
Table 17: Product Profile - Optaflu
Table 18: Optaflu SWOT Analysis, 2012
Table 19: Overall Unmet Needs - Current Level of Attainment
Table 20: Clinical Unmet Needs - Gap Analysis, 2012
Table 21: Sales Forecasts ($m) for Influenza Vaccines in France, 2012-2022
Table 22: Key Events Impacting Sales of Influenza Vaccines in France, 2012
Table 23: Influenza Vaccine Market - Drivers and Barriers, 2012
Table 24: Key Launch Dates
Table 25: Physicians Surveyed, By Country

1.2 List of Figures
Figure 1: Influenza Virus Structure
Figure 2: Sales for Influenza Vaccines in France by Route of Administration, 2012-2022

Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit

http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: PharmaPoint: Seasonal Influenza Vaccines France Drug Forecast and Market Analysis
Web Address: http://www.researchandmarkets.com/reports/2368641/
Office Code: SC6IYJVK

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Description</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF)</td>
<td>Single User</td>
<td>USD 4995</td>
</tr>
<tr>
<td></td>
<td>Site License</td>
<td>USD 9990</td>
</tr>
<tr>
<td></td>
<td>Enterprisewide</td>
<td>USD 14985</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title:  Mr □ Mrs □ Dr □ Miss □ Ms □ Prof □
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: __________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World